Department of Dentistry, University Center of Brás Cubas, Mogi das Cruzes, SP, Brazil.
Department of Dentistry, University of Taubaté, Taubaté, SP, Brazil.
Am J Case Rep. 2020 Nov 17;21:e924377. doi: 10.12659/AJCR.924377.
BACKGROUND Osteonecrosis of the jaw is a condition manifesting as necrotic bone for 8 weeks or more, with no history of radiotherapy. It is linked to the use of antiresorptive drugs, such as bisphosphonates and denosumab. We discuss in this case report the importance of infection control during clinical procedures in patients taking antiresorptives. CASE REPORT Our case report describes a 52-year-old woman who had received zoledronic acid injections for 7 years, who presented with osteonecrosis of the jaw in the region of teeth 24, 25, and 26, with no local trauma. The report proceeds to describe the extraction of these teeth. After the dental extractions, she did not have any recurrence of the lesion, and she is currently in follow-up care. CONCLUSIONS Osteonecrosis of the jaw can be prevented through infection control and local trauma prevention. Patients who are taking antiresorptive drugs must receive special care from dental surgeons and doctors, and receive the necessary oral treatments before starting drug therapy.
颌骨骨坏死是一种表现为 8 周或以上的坏死骨,且无放射治疗史的疾病。它与抗吸收药物的使用有关,如双磷酸盐类和地舒单抗。在本病例报告中,我们讨论了在服用抗吸收药物的患者的临床操作过程中,感染控制的重要性。
本病例报告描述了一名 52 岁女性,她接受唑来膦酸注射治疗已 7 年,出现了 24、25 和 26 牙齿区域的颌骨骨坏死,且无局部创伤。报告接着描述了这些牙齿的拔除过程。在拔牙后,她的病变没有复发,目前正在接受随访。
通过感染控制和局部创伤预防可以防止颌骨骨坏死。服用抗吸收药物的患者必须接受牙医和医生的特殊护理,并在开始药物治疗前接受必要的口腔治疗。